- CNS Pharmaceuticals recently appointed Amy Mahery, a biotech commercialization leader, to its Board of Directors
- Ms. Mahery brings over 20 years’ experience, having worked with small and large companies, and has held diverse commercial leadership roles in the U.S. and globally
- The company believes Ms. Mahery’s guidance, insight, and vast pharma industry network will indeed be invaluable as the company advances Berubicin, its flagship drug candidate, toward completion of its global potentially pivotal clinical trial and potential regulatory approval
- The company recently completed the enrollment of patients in its potentially pivotal global clinical trial
- Ms. Mahery believes Berubicin represents an opportunity to provide a solution for patients with GBM, the most aggressive type of brain cancer
With a fervent commitment to developing and commercializing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system, clinical-stage biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) continues to advance its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization. To boost these efforts, the company has enlisted an experienced, growing team. Recently, CNS Pharmaceuticals appointed Amy Mahery to its Board of Directors (https://ibn.fm/huSZ8).
A biotech commercialization leader, Ms. Mahery has built an illustrious career that spans more than 20 years. During this period, she has gained commercial expertise working with small and large companies in common and rare conditions, as well as across several therapeutic areas. She has held diverse commercial leadership roles in the U.S. and globally, spanning sales, marketing, and market access where she has been part of teams that commercialized and launched drugs in various therapeutic areas, from oncology and neurology to immunology.
In her current role as the Chief Commercial Officer of Roivant Sciences (NASDAQ: ROIV), a publicly traded biopharmaceutical company with a $9 billion market cap, Ms. Mahery is playing a vital role in facilitating Roivant’s transformation from a clinical development-focused company to an end-to-end biotech leader. She has worked to establish the company’s commercial operations and capabilities, efforts that have seen Roivant achieve profitable growth across its entire portfolio of over 10 affiliate companies called Vants. Ms. Mahery provides direct commercial leadership to the Vants during the start-up phase. Prior to taking up this role, she held multiple leadership roles at EMD Serono, Inc., a healthcare subsidiary of Merck KGaA.
“We are incredibly pleased to welcome Amy to the Board. She is a proven commercial leader with a wealth of knowledge and expertise amassed over the course of her 20+ years in the industry. As the company continues to advance Berubicin toward completion of its global potentially pivotal clinical trial and potential regulatory approval, her guidance, insight, and vast pharma industry network will truly be invaluable,” conveyed Faith L. Charles, Chair of the CNS Pharmaceuticals Board of Directors. “We remain committed to serving GBM patients in desperate need of a treatment, and look forward to leveraging Amy’s extensive experience and commercial leadership to assist in positioning the company for success.”
A strong supporter of innovation that brings value to patients, organizations, and society, Ms. Mahery lauded CNS Pharmaceuticals and its efforts to fill gaps in areas with high unmet medical needs, such as glioblastoma multiforme (“GBM”) treatment, saying, “I have been intrigued by the company’s pivotal trial design for Berubicin and was further compelled by the successful outcome from the recent interim analysis, the rapid pace of enrollment, and strong management team.”
Ms. Mahery believes Berubicin represents an opportunity to provide a solution for patients with GBM, the most aggressive type of brain cancer. Berubicin, an anthracycline, appears to cross the blood-brain barrier and kill cancer cells, as results from the completed Phase 1 human clinical trial show. The trial demonstrated positive responses that included one durable complete response.
CNS Pharmaceuticals is currently undertaking a potentially pivotal study of Berubicin for the treatment of GBM. The company completed in January the planned enrollment of 247 participants across 46 clinical trial sites in the U.S., Italy, France, Spain, and Switzerland (https://ibn.fm/dPOwp). The company remains hopeful in its efforts to address GBM and intends to take advantage of the extensive expertise of Ms. Mahery and other members of its capable team to drive success.
For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com
MissionIR is powered by IBN
